Imugene Limited Employee Directory
Biotechnology ResearchNew South Wales, Australia11-50 Employees
Imugene Limited is a clinical-stage biotechnology company focused on immuno-oncology, aiming to activate the patient’s immune system to fight and eradicate tumors. Its pipeline includes immunotherapy approaches such as B-cell vaccines and an oncolytic virotherapy called CF33, designed to treat a range of cancers in combination with standard therapies and emerging immunotherapies. Based in Sydney, New South Wales, the company operates as a small to mid-sized biotechnology firm supported by a team of international cancer experts with broad experience in developing new cancer therapies for global markets. In 2025, Imugene announced participation at ASH 2025, with an abstract related to its azer-cel program selected for oral presentation. The company is listed on the Australian Securities Exchange under the ticker IMU.